‘Open access’ generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies

References

• AYRTON, J., PLUMB, R., LEAVENS, W. J., MALLETT, D., DICKINS, M. and DEAR, G. H., 1998, Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. Rapid Communications in Mass Spectrometry, 12, 217–224.
   PubMed Web of Science ®Google Scholar
• BALL, S. E., AHERN, D., SCATINA, J. and KAO, J., 1997, Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism: comparative studies with selected SSRIs and effects on human hepatic CYP 3A4, CYP 2C9 and CYP 1A2. British Journal of Clinical Pharmacology, 43, 619–626.
   PubMed Web of Science ®Google Scholar
• BUSBY, W. F., ACKERMANN, J. M. and CRESPI, C. L., 1999, Effect of methanol, ethanol, dimethylsulfoxide and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metabolism and Disposition, 27, 853–862.
   Web of Science ®Google Scholar
• CHAURET, N., GAUTHIER, A., MARTIN, J. and NICOLL-GRIFFITH, D. A., 1997, In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat and horse. Drug Metabolism and Disposition, 25, 1130–1136.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L., MILLER, V. P. and PENMAN, B. W., 1997, Microtiter plate assays for inhibition of human drug metabolizing cytochromes P450. Analytical Biochemistry, 248, 188–190.
   PubMed Web of Science ®Google Scholar
• EASTERBROOK, J., Lu, C., SAKAI, Y. and Li, A. P., 2001, Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metabolism and Disposition, 29, 141–144.
   PubMed Web of Science ®Google Scholar
• FLOCKHART, D. A., DRICI, M. D., KERBUSCH, T., SOUKHOVA, N., RICHARD, E., PEARLE, P. L., MAHAL, S. K. and BABB, V. J., 2000, Studies on the mechanism of a fatal clarithromycin—pimozide interaction in a patient with Tourette syndrome. Journal of Clinical Psychopharmacology, 20, 317–324.
   PubMed Web of Science ®Google Scholar
• HERINGS, R. M., STRICKER, B. H., LEUFKENS, H. G., BAKKER, A., STURMANS, F. and URQUHART, J., 1993, Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands. Pharmacy World and Science, 15, 212–218.
   PubMedGoogle Scholar
• HESSE, L. M., VENKATAKRISHNAN, K., COURT, M. H., VON MOLTKE, L. L., DUAN, S. X., SHADER, R. I. and GREENBLATT, D. J., 2000, CYP 2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metabolism and Disposition, 28, 1176–1183.
   PubMed Web of Science ®Google Scholar
• HICKMAN, D., WANG, J. P., WANG, Y. I. and UNADKAT, J. D., 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metabolism and Disposition, 26, 207–215.
   PubMed Web of Science ®Google Scholar
• HONIG, P. K., WORTHAM, D. C., ZAMANI, K., CONNER, D. P., MULLIN, J. C. and CANTILENA, L. R., 1993, Terfenadine—ketoconazole interaction: pharmacokinetic and cardiographic consequences. Journal of the American Medical Association, 269, 1513–1518.
   PubMed Web of Science ®Google Scholar
• Ko, J. W., SUKHOVA, N., THACKER, D., CHEN, P. and FLOCKHART, D. A., 1997, Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853–862.
   PubMed Web of Science ®Google Scholar
• Li, D. N., PRITCHARD, M. P., HANLON, S. P., BURCHELL, B., WOLF, C. R. and FRIEDBERG, T., 1999, Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism. Journal of Pharmacology and Experimental Therapeutics, 289, 661–667.
   PubMed Web of Science ®Google Scholar
• MICHALETS, E. L. and WILLIAMS, C. R., 2000, Drug interactions with cisapride: clinical implications. Clinical Pharmacokinetics, 39, 49–75.
   PubMed Web of Science ®Google Scholar
• MOODY, G. C., GRIFFIN, S. J., MATHER, A. N., MCGINNITY, D. F. and RIELY, R. J., 1999, Fully automated analysis of activities catalyzed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica, 29, 53–75.
   PubMed Web of Science ®Google Scholar
• PECK, C. C., TEMPLE, R. and COLLINS, J. M., 1993, Understanding consequences of concurrent therapies. Journal of the American Medical Association, 169, 1550–1552.
   Google Scholar
• RAO, N. V. S. M., BIJU, B., RAMESH, M. and SRINIVAS, N. R., 2003, Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard. Biomedical Chromatography, 17,417–420.
   Google Scholar
• SCOTT, R. J., PALMER, J., LEWIS, I. A. S. and PLEASANCE, S., 1999, Determination of a `GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 13, 2305–2319.
   Google Scholar
• YUAN, R., MADANI, S., WEI, X. X., REYNOLDS, K. and HUANG, S. M., 2002, Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metabolism and Disposition, 30, 1311–1319.
   PubMed Web of Science ®Google Scholar